Literature DB >> 33534955

The optimal cut-off value in fit-based colorectal cancer screening: An observational study.

Sisse Helle Njor1,2,3, Berit Andersen1,2,3, Lennart Friis-Hansen3,4, Niels de Haas3,5, Dorte Linnemann3,6, Henrik Nørgaard3,7, Ole Roikjaer3,8, Bo Søndergaard3,9, Morten Rasmussen3,10.   

Abstract

BACKGROUND: Colorectal cancer (CRC) screening programs using fecal immunochemical test (FIT) have to choose a cut-off value to decide which citizens to recall for colonoscopy. The evidence on the optimal cut-off value is sparse and based on studies with a low number of cancer cases.
METHODS: This observational study used data from the Danish Colorectal Cancer Screening Database. Sensitivity and specificity were estimated for various cut-off values based on a large number of cancers. Traditionally optimal cut-off values are found by weighting sensitivity and specificity equally. As this might result in too many unnecessary colonoscopies we also provide optimal cut-off values for different weighting of sensitivity and specificity/number of needed colonoscopies to detect one cancer.
RESULTS: Weighting sensitivity and specificity equally gives an optimal cut-off value of 45 ng Hb/ml. This, however, means making 24 colonoscopies to detect one cancer. Weighting sensitivity lower and for example, aiming at making about 16 colonoscopies to detect one cancer, gives an optimal cut-off value of 125 ng Hb/ml.
CONCLUSIONS: The optimal cut-off value in an FIT population-based screening program is 45 ng Hb/ml, when as traditionally sensitivity and specificity are weighted equally. If, however, 24 colonoscopies needed to detect one cancer is too huge a burden on the health care system and the participants, 80, 125, 175, and 350 ng Hb/ml are optimal cut-off values when only 19/16/14/10 colonoscopies are accepted to find one cancer.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  capacity building; colorectal neoplasms; mass screening; sensitivity; specificity

Mesh:

Year:  2021        PMID: 33534955      PMCID: PMC7940214          DOI: 10.1002/cam4.3761

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  14 in total

1.  Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples.

Authors:  Enrique F Schisterman; Neil J Perkins; Aiyi Liu; Howard Bondell
Journal:  Epidemiology       Date:  2005-01       Impact factor: 4.822

2.  Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark.

Authors:  Mette Bach Larsen; Sisse Njor; Peter Ingeholm; Berit Andersen
Journal:  Gastroenterology       Date:  2018-04-05       Impact factor: 22.682

3.  Estimation of the optimal cut off point in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme.

Authors:  M Itoh; K Takahashi; H Nishida; K Sakagami; T Okubo
Journal:  J Med Screen       Date:  1996       Impact factor: 2.136

Review 4.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

5.  The Danish National Patient Register.

Authors:  Elsebeth Lynge; Jakob Lynge Sandegaard; Matejka Rebolj
Journal:  Scand J Public Health       Date:  2011-07       Impact factor: 3.021

6.  Patterns of occult bleeding in asymptomatic colorectal cancer.

Authors:  D A Ahlquist; D B McGill; J L Fleming; S Schwartz; H S Wieand; J Rubin; C G Moertel
Journal:  Cancer       Date:  1989-05-01       Impact factor: 6.860

7.  Three years of colorectal cancer screening in Denmark.

Authors:  Sisse Helle Njor; Lennart Friis-Hansen; Berit Andersen; Bo Søndergaard; Dorte Linnemann; Jens Christian Riis Jørgensen; Ole Roikjær; Morten Rasmussen
Journal:  Cancer Epidemiol       Date:  2018-10-04       Impact factor: 2.984

8.  Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.

Authors:  T R de Wijkerslooth; E M Stoop; P M Bossuyt; G A Meijer; M van Ballegooijen; A H C van Roon; I Stegeman; R A Kraaijenhagen; P Fockens; M E van Leerdam; E Dekker; E J Kuipers
Journal:  Am J Gastroenterol       Date:  2012-07-31       Impact factor: 10.864

9.  Selecting a Cut-off for Colorectal Cancer Screening With a Fecal Immunochemical Test.

Authors:  Hermann Brenner; Simone Werner
Journal:  Clin Transl Gastroenterol       Date:  2017-08-03       Impact factor: 4.488

10.  The Optimal Cut-Off Level of The Fecal Immunochemical Test For Colorectal Cancer Screening in a Country with Limited Colonoscopy Resources: A Multi-Center Study from Thailand

Authors:  Satimai Aniwan; Thawee Ratanachu Ek; Supot Pongprasobchai; Julajak Limsrivilai; Ong Ard Praisontarangkul; Pises Pisespongsa; Pisaln Mairiang; Apichat Sangchan; Jaksin Sottisuporn; Naruemon Wisedopas; Pinit Kullavanijaya; Rungsun Rerknimitr
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01
View more
  2 in total

1.  Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.

Authors:  Mette Kielsholm Thomsen; Lars Pedersen; Rune Erichsen; Timothy L Lash; Henrik T Sørensen; Ellen M Mikkelsen
Journal:  Br J Cancer       Date:  2022-01-20       Impact factor: 9.075

Review 2.  Optimal Strategies for Colorectal Cancer Screening.

Authors:  Shailavi Jain; Jetrina Maque; Artin Galoosian; Antonia Osuna-Garcia; Folasade P May
Journal:  Curr Treat Options Oncol       Date:  2022-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.